Janux Therapeutics (JANX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

JANX Stock Forecast

Janux Therapeutics stock forecast is as follows: an average price target of $61.20 (represents a 21.65% upside from JANX’s last price of $50.31) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

JANX Price Target

The average price target for Janux Therapeutics (JANX) is $61.20 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $42.00. This represents a potential 21.65% upside from JANX's last price of $50.31.

JANX Analyst Ratings

Buy

According to 3 Wall Street analysts, Janux Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for JANX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Janux Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 24, 2024	David Dai	UBS	-	-	33.33%	37.15%
Sep 05, 2024	Bradley Canino	Stifel Nicolaus	-	-	60.15%	39.14%
Aug 09, 2024	George Farmer	Scotiabank	-	-	15.10%	-16.52%
May 30, 2024	George Farmer	Scotiabank	-	-	-1.26%	-6.58%
May 13, 2024	Swayampakula Ramakanth	H.C. Wainwright	-	-	26.94%	25.22%
Mar 20, 2024	Kaveri Pohlman	BTIG	-	-	58.45%	23.24%

Row per page

Go to

The latest Janux Therapeutics stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $69.00, which represents a 33.33% increase from the stock price at the time of the forecast ($51.75), and a 37.15% increase from JANX last price ($50.31).

Janux Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	2	6
Avg Price Target	$69.00	$69.50	$58.83
Last Closing Price	$50.31	$50.31	$50.31
Upside/Downside	37.15%	38.14%	16.94%

In the current month, the average price target of Janux Therapeutics stock is $69.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 37.15% increase as opposed to Janux Therapeutics's last price of $50.31. This month's average price target is down -0.72% compared to last quarter, and up 17.29% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 24, 2024	Wedbush	Sector Perform	Sector Perform	Hold
Oct 24, 2024	UBS	Underperform	Underperform	Hold
Oct 24, 2024	UBS		Buy	Initialise
Sep 06, 2024	Wedbush	Sector Perform	Sector Perform	Hold
Sep 06, 2024	Scotiabank	Underperform	Underperform	Hold
Aug 09, 2024	Wedbush	Sector Perform	Sector Perform	Hold
Aug 09, 2024	Scotiabank	Underperform	Underperform	Hold
Aug 09, 2024	Scotiabank	Sector Perform	Sector Perform	Hold
May 30, 2024	Wedbush	Sector Perform	Sector Perform	Hold
May 30, 2024	Scotiabank	Underperform	Underperform	Hold

Row per page

Go to

Janux Therapeutics's last stock rating was published by Wedbush on Oct 24, 2024. The company gave JANX a "Sector Perform" rating, the same as its previous rate.

Janux Therapeutics Financial Forecast

Janux Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.52M	$1.06M	$2.05M	$2.85M	$1.81M	$2.37M	$1.59M	$1.62M	$1.16M	$482.00K
Avg Forecast	$705.40K	$669.19K	$634.84K	$602.25K	$312.50K	$312.50K	$250.00K	$250.00K	$1.15M	$1.50M	$772.00K	$878.57K	$750.00K	$845.50K	$875.00K	$672.35K	$805.50K	$742.58K	$650.00K	$810.40K	$433.33K	$133.33K	$133.33K
High Forecast	$705.40K	$669.19K	$634.84K	$602.25K	$312.50K	$312.50K	$250.00K	$250.00K	$1.15M	$1.50M	$772.00K	$878.78K	$811.22K	$845.75K	$875.00K	$672.35K	$805.50K	$742.58K	$650.00K	$810.40K	$433.33K	$133.33K	$133.33K
Low Forecast	$705.40K	$669.19K	$634.84K	$602.25K	$312.50K	$312.50K	$250.00K	$250.00K	$1.15M	$1.50M	$772.00K	$878.36K	$688.77K	$845.25K	$875.00K	$672.35K	$805.50K	$742.58K	$650.00K	$810.40K	$433.33K	$133.33K	$133.33K
# Analysts	6	4	4	6	4	3	7	9	9	1	1	1	3	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	2.98%	1.21%	3.05%	3.53%	2.44%	3.64%	1.96%	3.73%	8.69%	3.62%

Janux Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $750.00K, with a low forecast of $688.77K, and a high forecast of $811.22K. JANX's average Quarter revenue forecast represents a -70.20% decrease compared to the company's last Quarter revenue of $2.52M (Sep 23).

Janux Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	6	4	4	6	4	3	7	9	9	1	1	1	3	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-15.81M	$-20.75M	$-20.28M	$-18.27M	$-17.77M	$-17.15M	$-13.46M	$-13.42M	$-10.74M	$-6.19M
Avg Forecast	$-141.08K	$-133.84K	$-126.97K	$-120.45K	$-62.50K	$-62.50K	$-50.00K	$-50.00K	$-229.95K	$-299.04K	$-154.40K	$-175.71K	$-150.00K	$-169.10K	$-175.00K	$-134.47K	$-161.10K	$-148.52K	$-130.00K	$-14.98M	$-86.67K	$-26.67K	$-17.65M
High Forecast	$-141.08K	$-133.84K	$-126.97K	$-120.45K	$-62.50K	$-62.50K	$-50.00K	$-50.00K	$-229.95K	$-299.04K	$-154.40K	$-175.67K	$-137.75K	$-169.05K	$-175.00K	$-134.47K	$-161.10K	$-148.52K	$-130.00K	$-11.98M	$-86.67K	$-26.67K	$-14.12M
Low Forecast	$-141.08K	$-133.84K	$-126.97K	$-120.45K	$-62.50K	$-62.50K	$-50.00K	$-50.00K	$-229.95K	$-299.04K	$-154.40K	$-175.76K	$-162.24K	$-169.15K	$-175.00K	$-134.47K	$-161.10K	$-148.52K	$-130.00K	$-17.98M	$-86.67K	$-26.67K	$-21.18M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	93.51%	118.56%	150.82%	113.38%	119.67%	131.95%	0.90%	154.80%	402.72%	0.35%

undefined analysts predict JANX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Janux Therapeutics's previous annual EBITDA (undefined) of $NaN.

Janux Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	6	4	4	6	4	3	7	9	9	1	1	1	3	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-11.57M	$-17.51M	$-14.18M	$-11.26M	$-14.04M	$-16.52M	$-13.15M	$-13.34M	$-10.77M	$-6.21M
Avg Forecast	$-23.51M	$-20.25M	$-18.83M	$-17.73M	$-30.57M	$-26.66M	$-24.84M	$-23.50M	$-22.52M	$-17.88M	$-16.97M	$-18.10M	$-22.68M	$-25.68M	$-27.42M	$-26.55M	$-26.29M	$-25.46M	$-17.24M	$-15.22M	$-14.70M	$-9.62M	$-17.69M
High Forecast	$-23.51M	$-20.25M	$-18.83M	$-17.73M	$-30.57M	$-26.66M	$-24.84M	$-18.27M	$-18.33M	$-17.88M	$-16.97M	$-18.10M	$-18.39M	$-25.68M	$-27.42M	$-26.55M	$-26.29M	$-25.46M	$-17.24M	$-12.18M	$-14.70M	$-9.62M	$-14.15M
Low Forecast	$-23.51M	$-20.25M	$-18.83M	$-17.73M	$-30.57M	$-26.66M	$-24.84M	$-26.63M	$-25.14M	$-17.88M	$-16.97M	$-18.10M	$-25.75M	$-25.68M	$-27.42M	$-26.55M	$-26.29M	$-25.46M	$-17.24M	$-18.27M	$-14.70M	$-9.62M	$-21.22M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.45%	0.64%	0.53%	0.43%	0.55%	0.96%	0.86%	0.91%	1.12%	0.35%

Janux Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. JANX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Janux Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	6	4	4	6	4	3	7	9	9	1	1	1	3	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$6.44M	$6.88M	$6.46M	$5.68M	$6.10M	$5.54M	$4.95M	$3.94M	$3.66M	$2.00M
Avg Forecast	$1.50M	$1.43M	$1.35M	$1.28M	$666.18K	$666.18K	$532.95K	$532.95K	$2.45M	$3.19M	$1.65M	$1.87M	$1.60M	$1.80M	$1.87M	$1.43M	$1.72M	$1.58M	$1.39M	$1.73M	$923.77K	$284.24K	$284.24K
High Forecast	$1.50M	$1.43M	$1.35M	$1.28M	$666.18K	$666.18K	$532.95K	$532.95K	$2.45M	$3.19M	$1.65M	$1.87M	$1.73M	$1.80M	$1.87M	$1.43M	$1.72M	$1.58M	$1.39M	$1.73M	$923.77K	$284.24K	$284.24K
Low Forecast	$1.50M	$1.43M	$1.35M	$1.28M	$666.18K	$666.18K	$532.95K	$532.95K	$2.45M	$3.19M	$1.65M	$1.87M	$1.47M	$1.80M	$1.87M	$1.43M	$1.72M	$1.58M	$1.39M	$1.73M	$923.77K	$284.24K	$284.24K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	3.57%	3.69%	4.51%	3.31%	3.85%	4.00%	2.86%	4.26%	12.86%	7.03%

Janux Therapeutics's average Quarter SG&A projection for Dec 23 is $1.60M, based on 3 Wall Street analysts, with a range of $1.47M to $1.73M. The forecast indicates a -75.17% fall compared to JANX last annual SG&A of $6.44M (Sep 23).

Janux Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	6	4	4	6	4	3	7	9	9	1	1	1	3	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.25	$-0.42	$-0.34	$-0.27	$-0.34	$-0.40	$-0.32	$-0.32	$-0.26	$-0.62
Avg Forecast	$-0.43	$-0.37	$-0.34	$-0.32	$-0.56	$-0.49	$-0.45	$-0.43	$-0.41	$-0.33	$-0.31	$-0.33	$-0.42	$-0.47	$-0.50	$-0.49	$-0.48	$-0.47	$-0.32	$-0.32	$-0.27	$-0.18	$-0.14
High Forecast	$-0.43	$-0.37	$-0.34	$-0.32	$-0.56	$-0.49	$-0.45	$-0.33	$-0.34	$-0.33	$-0.31	$-0.33	$-0.34	$-0.47	$-0.50	$-0.49	$-0.48	$-0.47	$-0.32	$-0.32	$-0.27	$-0.18	$-0.14
Low Forecast	$-0.43	$-0.37	$-0.34	$-0.32	$-0.56	$-0.49	$-0.45	$-0.49	$-0.46	$-0.33	$-0.31	$-0.33	$-0.47	$-0.47	$-0.50	$-0.49	$-0.48	$-0.47	$-0.32	$-0.32	$-0.27	$-0.18	$-0.14
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.53%	0.84%	0.70%	0.56%	0.73%	1.26%	1.00%	1.19%	1.47%	4.43%

According to undefined Wall Street analysts, Janux Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to JANX previous annual EPS of $NaN (undefined).

Janux Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ANTX	AN2 Therapeutics	-	-	552.99%	Buy
MOLN	Molecular Partners	-	-	448.20%	Buy
AVTE	Aerovate Therapeutics	-	-	388.72%	Hold
ANEB	Anebulo Pharmaceuticals	-	-	310.96%	Buy
ACRV	Acrivon Therapeutics	-	-	233.28%	Buy
FENC	Fennec Pharmaceuticals	-	-	196.05%	Buy
RZLT	Rezolute	-	-	174.95%	Buy
ELYM	Eliem Therapeutics	-	-	154.40%	Buy
MLYS	Mineralys Therapeutics	-	-	140.19%	Buy
ADAG	Adagene	-	-	128.31%	Buy
KROS	Keros Therapeutics	-	-	83.48%	Buy
HRMY	Harmony Biosciences	-	-	43.41%	Buy
EWTX	Edgewise Therapeutics	-	-	39.75%	Buy
JANX	Janux Therapeutics	-	-	21.65%	Buy
CYT	Cyteir Therapeutics	-	-	-33.77%	Sell

JANX Forecast FAQ

Is Janux Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Janux Therapeutics (JANX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of JANX's total ratings.

What is JANX's price target?

Janux Therapeutics (JANX) average price target is $61.2 with a range of $42 to $70, implying a 21.65% from its last price of $50.31. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Janux Therapeutics stock go up soon?

According to Wall Street analysts' prediction for JANX stock, the company can go up by 21.65% (from the last price of $50.31 to the average price target of $61.2), up by 39.14% based on the highest stock price target, and down by -16.52% based on the lowest stock price target.

Can Janux Therapeutics stock reach $80?

JANX's average twelve months analyst stock price target of $61.2 does not support the claim that Janux Therapeutics can reach $80 in the near future.

What is Janux Therapeutics's current price target trend?

1 Wall Street analyst forecast a $69 price target for Janux Therapeutics (JANX) this month, up 37.15% from its last price of $50.31. Compared to the last 3 and 12 months, the average price target increased by 38.14% and increased by 16.94%, respectively.

What are Janux Therapeutics's analysts' financial forecasts?

Janux Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.12M (high $1.12M, low $1.12M), average EBITDA is $-225K (high $-225K, low $-225K), average net income is $-106M (high $-100M, low $-109M), average SG&A $2.4M (high $2.4M, low $2.4M), and average EPS is $-1.933 (high $-1.837, low $-1.99). JANX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.61M (high $2.61M, low $2.61M), average EBITDA is $-522K (high $-522K, low $-522K), average net income is $-80.315M (high $-80.315M, low $-80.315M), average SG&A $5.57M (high $5.57M, low $5.57M), and average EPS is $-1.47 (high $-1.47, low $-1.47).

Did the JANX's actual financial results beat the analysts' financial forecasts?

Based on Janux Therapeutics's last annual report (Dec 2023), the company's revenue was $8.08M, beating the average analysts forecast of $3.14M by 157.19%. Apple's EBITDA was $-72.979M, beating the average prediction of $-629K by 11510.40%. The company's net income was $-58.293M, missing the average estimation of $-102M by -43.03%. Apple's SG&A was $26.14M, beating the average forecast of $6.7M by 290.16%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.873 by -99.93%. In terms of the last quarterly report (Sep 2023), Janux Therapeutics's revenue was $2.52M, beating the average analysts' forecast of $845.5K by 197.69%. The company's EBITDA was $-15.813M, beating the average prediction of $-169K by 9251.33%. Janux Therapeutics's net income was $-11.568M, missing the average estimation of $-25.675M by -54.95%. The company's SG&A was $6.44M, beating the average forecast of $1.8M by 257.19%. Lastly, the company's EPS was $-0.25, missing the average prediction of $-0.47 by -46.81%